Gamida Cell Ltd'

1
Gamida Cell Ltd.
Dr. Yael Margolin President CEO
2
Gamida Cells Keys For Success
Strong management
Strong IP
Big markets
Diversified line of therapeutics
Robust, validated manufacturing processes
Proprietary enabling technologies
3
Robust Manufacturing Processes
Gamida Cells technologies provide a
reproducible, significant enrichment of
stem/progenitor cells
Peled T et al., Exp Hematol. 200533(10)1092-100.
Prus E et al., Leukemia Lymphoma.
200445(3)583-9. Peled T et al., Exp Hematol.
200432547-55.  Peled T et al., Cytotherapy.
20046(4)344-55.
4
Gamida Cells Product Pipeline
Products for Bone Marrow Transplantation
Basic Research
Animal Models
Phase I/II
Phase II/III
Market
Products for Tissue Repair
5
How do the results of the StemEx trial compare
to similar controls?
StemEx Phase I/II Results
1CIBMTR, NCBP and EUROCORD patient records,
matching study eligibility criteria
6
StemEx

• Global pivotal registration study approved by the
  FDA under SPA, to be launched Summer 2007 11
  clinical sites (USA, EU, Israel)
• Product market launch anticipated in 2009
• Orphan Drug status in the US (March 2005)
• Market potential exceeding 1B
• StemEx is being developed by the Gamida Cell -
  Teva Joint Venture, with a 25M commitment by
  Teva
• Joint Venture owns manufacturing and marketing
  rights for StemEx in Hematological Diseases

7
CardioCure

• Bone marrow-derived autologous product of
  expanded cells to be used for cardiac
  regeneration post myocardial infarction
• Promising pre-clinical data show significant
  improvement in LVSF over controls (72) as well
  as over baseline (57)
• Phase I/II multi-center, randomized trial
  designed to test safety and efficacy of
  CardioCure as compared to standard care

8
Gamida Cell Organization
Board Ruben Krupik - Chair Mordechai Zisser Dr.
Hadar Ron Noam Karstaedt Dr. Yael Margolin
Management Yael Margolin, PhD, President and
CEO Tony Peled, Founder, VP CTO Yael Cohen,
MD, Medical Director Frida Grynspan, PhD, VP of
RD Yaron Daniely, PhD MBA, VP Business
Development Naftali Brikashvili, Head of
Finance Dorit Harati, Director, QA/QC Michal
Austin, Director, Regulatory Affairs Moshe
Marikovsky, PhD, Cardiac Project Manager Arik
Hasson, PhD, Diabetes Project Manager
Prof. Guillermo Sanz, Valencia, Spain Prof. Mary
Laughlin, Case Western Univ. Prof. Arnon Nagler,
Sheba Medical Center Prof. Ran Kornovsky, Rabin
Medical Center Prof. Shmuel Fuchs, Rabin Medical
Center
Scientific and Clinical Advisors Prof. Joanne
Kurtzberg, Duke Prof. Pablo Rubinstein, NY Blood
Cente Prof. Elizabeth Shpall, M. D.
Anderson Prof. Eliane Gluckman, St. Louis,
Paris Prof. Mary Horowitz, CIBMTR
9
Gamida Cell Today

• Advanced clinical programs with StemEx, MetCord
  and CardioCureTM
• Other pre-clinical programs in BM
  transplantation, PVD, CNS and diabetes
• Strong, global patent position
• Strategic partnering with Teva Pharmaceuticals
  with committed financing of the StemEx program
• 16M financing in 2006
• Experienced and committed management team